Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination

@article{Coleman2016HumanPT,
  title={Human papillomavirus type 16 viral load is decreased following a therapeutic vaccination},
  author={Hannah N. Coleman and William W. Greenfield and Shawna L. Stratton and Rita Vaughn and Alexander Kieber and Andrea M. Moerman-Herzog and Horace J. Spencer and Wilbur. C. Hitt and Charles Quick and Laura Hutchins and Samuel G. Mackintosh and Ricky D. Edmondson and Stephen W. Erickson and Mayumi Nakagawa},
  journal={Cancer Immunology, Immunotherapy},
  year={2016},
  volume={65},
  pages={563-573}
}
In the dose-escalation phase of a Phase I clinical trial in which six subjects each were vaccinated with PepCan at the 50, 100, 250, and 500 μg per peptide dose, the 50 μg dose showed the best histological regression rate. Ten additional subjects were vaccinated at this dose in the final dose phase. As with the dose-escalation phase, no dose-limiting… CONTINUE READING